Milestones

2014
Transition to Specialty Pharmaceutical Company by divesting Derm portfolio
Synacthen License for Canada
Launch of Baclofen
2013
Product Acquisition from Paladin Labs
Pamidronate Product Launch
2012
Veralac Product Launch
2011
Celestoderm Product Launch
2010
Vancomycin Product Launch
2009
Product Acquisition from Medicis
2008
Product Acquisition from Schering-Plough
Product Acquisition from Sandoz
2007
Aton Partnership (Merck Product Acquisition)
2005
Product Acquisition
Hydrosal Product Launch
2004
In-license Agreement
2003
Valeo Pharma founded
In-license agreement with Stiefel